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was estimated from €1218 to €1314 per patient/year depending
on different assumptions. These ﬁgures were higher than the
ideal expected average cost derived from guidelines (from €1007
to €1021 per patient/year), so yielding to a potential reduction
of €198 to €293 per patient/year. Monte-Carlo simulation
showed that about 13% of patients in the real word setting pre-
sented higher treatment costs than the maximum expected cost.
This proportion was much higher in moderate/severe patients
compared to mild patients (28.0% and 11.1% respectively).
CONCLUSIONS: An improvement of the adherence to GOLD
guidelines in Spain should have not only clinical implications for
COPD patients, but also an economic beneﬁt for the National
Health System. The potential savings in terms of medications
costs have been estimated around 20% of the observed costs.
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OBJECTIVES: To evaluate the prevalence of pulmonary hyper-
tension (PH) in Germany as epidemiological data for PH are
lacking. METHODS: The study followed a top-down approach,
based on German secondary statistics (based on ICD-10 codes)
and published literature. Several secondary statistics were taken
into account: Ofﬁcial German statistics on nationwide mortality
rates, ADT (“AbrechnungsDatenTransfer”) panel data from
“Zentralinstitut für die kassenärztliche Versorgung”, and diag-
nosis statistics from IMS Health. Data on prevalence of PH
related to connective tissue diseases, HIV infection, chronic
obstructive pulmonary disease (COPD), obstructive sleep apnoea
syndrome (OSAS), left ventricular systolic dysfunction (LVSD)
and pulmonary embolism (PE) were extracted from published lit-
erature 1990 to 2006 (peer-reviewed journals). Numbers of PH
cases were extrapolated for Germany, based on prevalence data
for the underlying diseases. RESULTS: Based on secondary sta-
tistics, number of cases in 2002 with idiopathic pulmonary arte-
rial hypertension (ICD I27.0) ranged from 1400 to almost 2900
cases, and number of cases with unspeciﬁc pulmonary heart
disease (ICD 27.9) ranges from 1700 up to 10,400 cases. Based
on literature data, prevalence of PH in patients with diseases like
connective tissue diseases or HIV infection ranges between 2480
and 11,160 cases. PH caused by LVSD affects about 380,000
patients. Cases of PH associated with COPD, OSAS or PE range
from 191,160 to 496,320. Summing up, between 574,100 and
889,900 patients were estimated to be affected by PH. CON-
CLUSION: The presented analysis is the ﬁrst robust estimation
of the prevalence of PH for Germany. Although the subgroup of
pulmonary arterial hypertension (WHO Group I) is shown to be
rare, secondary forms with estimated 570,000 to 900,000
patients affected by PH should be considered of relevance in
regard to socioeconomic aspects. With respect to these numbers
the medical community should focus on structural aspects of care
for patients with this severe disease.
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OBJECTIVES: To analyse the utilisation of drugs for treatment
of respiratory diseases (ATC group: R) within Slovakia between
1996 and 2004 and to asses the economic consequences of 
the medications. METHODS: For 1996–2004, the data about 
consumption of drugs for treatment of respiratory diseases were
collected, in accordance with classiﬁcation ATC and DDD mea-
surement unit. This analysis focused on the situation in asthma
medication in more detail. Data of wholesalers, who are legally
obliged provide this information to the Slovak Institute for Drug
Control, was used for the analysis. The results were expressed
in the numbers of packages, ﬁnance units (€) and deﬁned daily
doses per 1000 inhabitants per day (DID). RESULTS: A signiﬁ-
cant increase in the medication of respiratory diseases (in 1996
(98.29), in 2000 (92.55) and in 2004 (134.11) in term of DID
can be seen from this analysis. The results show the consump-
tion (in term of DID) of selective beta-2-adrenoreceptor agonists
in 1996 (3.61), in 2000 (3.80) and in 2004 (2.55), adrenergics
in 1996 (1.40), in 2000 (2.04) and in 2004 (5.91), glucocorti-
coids in 1996 (1.43), in 2000 (4.18) and in 2004 (5.26), anti-
cholinergics in 1996 (0.38), in 2000 (1.37) and in 2004 (2.70),
xanthines in 1996 (7.24), in 2000 (8.80) and in 2004 (7.20),
leukotriene receptor antagonists in 1997 (0.03), in 2000 (0.33)
and in 2004 (0.44). In ﬁnancial terms, the consumption of 
selective beta-2-adrenoreceptor agonists (€2,385,000), adrener-
gics (€9,679,000), glucocorticoids (€3,810,000), anticholinergics
(€1,464,000), xanthines (€1,366,000), leukotriene receptor
antagonists (€1,649,000) for the year 2004 can be seen from this
study. CONCLUSIONS: Usage of generic drugs for the treatment
of respiratory diseases brought about a dramatic increase in the
consumption of drugs in this ﬁeld but the ﬁnancial expenditures
for health insurance funds have been remained under control.
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OBJECTIVES: Expected Value of Perfect Information (EVPI)
analysis is a natural extension of probabilistic modelling and
provides information about the value of collecting additional
information to eliminate or reduce uncertainty. A partial EVPI
analysis provides information about the model parameters for
which the collection of additional data is most useful. The objec-
tive of this study is to determine the impact of additional data
collection on the remaining uncertainty in a probabilistic model
for the bronchodilator treatment of patients with chronic
obstructive pulmonary disease (COPD). The value of additional
information is weighted against the costs of collecting the data.
METHODS: We used a probabilistic Markov model with a time-
horizon of 5 years. Primary outcome parameters were the costs
per QALY. Stochastic input parameters of the model included
probabilities to transition between disease states, probabilities to
experience an exacerbation, and utilities and resource use asso-
ciated with disease states and exacerbations. Because utilities
proved to contribute substantially to the overall EVPI, additional
data about utilities associated with COPD severity states were
collected in 1235 patients participating in a randomised clinical
trial. RESULTS: Before collecting additional data the overall
